InsiderSignalSign in

← Insider buys

IMVT

Immunovant, Inc. · Healthcare

Insiders bought $350.0M of Immunovant, Inc. in the last 12 months

1 insider bought on 1 day.

$350.0MBought, 12 mo

$15.5MSold, 12 mo

$5.9BMarket cap

IMVT over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

Roivant Sciences Ltd.Director and 10% owner · 1 day$350.0M

IMVT after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

139 insider filings since 2020, newest first

Julia G. Butchko · Chief Development Officer

$107K−1.0%Nov 24

William L. Macias · Chief Medical Officer

$107K−1.0%Nov 24

Mark S. Levine · General Counsel

$107K−1.0%Nov 24

Mark S. Levine · General Counsel

$142K−1.0%Oct 27

Eva Renee Barnett · CFO

$168K−1.0%Oct 11

Julia G. Butchko · Chief Development Officer

Peter Salzmann · CEO

$190K−1.0%Oct 6

Peter Salzmann · CEO

$1.3M−6.0%Sep 1

Mark S. Levine · General Counsel

$249K−4.0%Aug 25

Eva Renee Barnett · CFO

$292K−4.0%Aug 25

Julia G. Butchko · Chief Development Officer

$250K−3.0%Aug 25

William L. Macias · Chief Medical Officer

$250K−4.0%Aug 25

Peter Salzmann · CEO

$2.2M−9.0%Aug 16

Peter Salzmann · CEO

$2.2M−8.0%Aug 8

Mark S. Levine · General Counsel

$85K−1.0%Jul 27

Eva Renee Barnett · CFO

$68K−1.0%Jul 20

Peter Salzmann · CEO

Julia G. Butchko · Chief Development Officer

Mark S. Levine · General Counsel

$43K−1.0%Apr 26

Eva Renee Barnett · CFO

$52K−1.0%Apr 19

Peter Salzmann · CEO

Mark S. Levine · General Counsel

$188K−4.0%Jan 27

Peter Salzmann · CEO

Julia G. Butchko · Chief Dev., Tech. Officer

$1.0M−15.0%Jan 13

Eva Renee Barnett · CFO

$76K−2.0%Jan 13

William L. Macias · Chief Medical Officer

$746K−14.0%Jan 13

Peter Salzmann · CEO

Eva Renee Barnett · CFO

$118K−4.0%Oct 13

Julia G. Butchko · Chief Dev., Tech. Officer

$38K−2.0%Apr 14

Peter Salzmann · CEO

$113K−3.0%Apr 14

Julia G. Butchko · Chief Dev., Tech. Officer

$401K−16.0%Jan 11

Eva Renee Barnett · CFO

$217K−15.0%Jan 11

Peter Salzmann · CEO

$907K−18.0%Jan 11

William L. Macias · Chief Medical Officer

$222K−12.0%Jan 7

Douglas J. Hughes · Director

$150K+45.0%Aug 30

George Migausky V · Director

$54K+12.0%Aug 20

Atul Pande · Director

$40K+12.0%Aug 16

Andrew J. Fromkin · Director

$43K+14.0%Aug 11

Roivant Sciences Ltd. · 10% owner

$12.5M+1.0%Sep 4

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.